Avanos Medical Insider Lowered Holding By 15% During Last Year
Avanos Medical Insider Lowered Holding By 15% During Last Year
From what we can see, insiders were net sellers in Avanos Medical, Inc.'s (NYSE:AVNS ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.
从我们所看到的来看,过去12个月中,Avanos Medical,Inc.(纽交所:AVNS)的内部人士是净卖家。也就是说,内部人士卖出了比购买更多的股票。
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
虽然我们不认为股东应该简单地跟随内部交易,但我们认为监控内部人士的行动是很合理的。
Avanos Medical Insider Transactions Over The Last Year
过去一年中的Avanos Medical内部交易
The Senior VP, Michael Greiner, made the biggest insider sale in the last 12 months. That single transaction was for US$153k worth of shares at a price of US$19.16 each. That means that an insider was selling shares at slightly below the current price (US$23.58). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 15% of Michael Greiner's holding. Michael Greiner was the only individual insider to sell shares in the last twelve months.
高级副总裁Michael Greiner在过去12个月中做出了最大的内部交易。那单交易的价值为15.3万美元,每股价格为19.16美元。也就是说,内部人士以略低于当前价格(23.58美元)的价格出售股票。一般来说,如果内部人员以低于当前价格的价格出售股票,那么这是令人沮丧的,因为这表明他们对较低估值感到满意。虽然内部交易的售出不是什么积极的迹象,但我们不能确定这是否意味着内部人员认为股票价值已经充分体现,因此这只是一个弱迹象。值得注意的是,这笔交易仅占Michael Greiner持有的股份的15%。Michael Greiner是过去12个月中唯一一个个人内部人士出售股票的人。
You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
以下是公司和个人过去12个月的内部交易的可视化描述。如果单击图表,您可以查看所有个人交易,包括股票价格、个人和日期!
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240820/0-32265ad40679ef98e91bc29288f77b0c-0-701ef4d435529625bf5280bc1378270f.png/big)
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
如果你喜欢购买内部人员正在购买而不是销售的股票,那么你可能会喜欢这份免费的公司列表。(提示:它们中的大部分都被忽视了。)
Does Avanos Medical Boast High Insider Ownership?
Avanos Medical是否拥有高比例内部持股?
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Avanos Medical insiders own 1.5% of the company, worth about US$15m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
测试公司领导人和其他股东之间关系的另一种方法是查看他们拥有多少股份。我们通常希望看到相当高的内部持股比例。看来Avanos Medical的内部人士拥有该公司的1.5%股份,价值约1500万美元。我们确实在其他地方看到过更高比例的内部持股,但这些持股足以表明内部人士与其他股东的利益基本保持一致。
So What Does This Data Suggest About Avanos Medical Insiders?
这些数据对Avanos Medical内部人员意味着什么?
There haven't been any insider transactions in the last three months -- that doesn't mean much. Our analysis of Avanos Medical insider transactions leaves us cautious. But it's good to see that insiders own shares in the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 1 warning sign for Avanos Medical you should be aware of.
在过去的三个月中没有内部交易——这意义不大。我们对Avanos Medical内部交易的分析让我们保持谨慎。但看到内部人士拥有公司的股票是好事。虽然了解内部人员持股和交易的情况很好,但在做出任何投资决策之前,我们也要考虑股票面临的风险。话说回来:我们已经发现了1个Avanos Medical警告标志,您应该注意。
Of course Avanos Medical may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,Avanos Medical可能不是最好的股票选择。因此,您可能希望查看这些高质量公司的免费收藏。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。